Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03605862 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Nitazoxanide in the Treatment of Colds Due to Enterovirus/Rhinovirus Infection
A Phase 3 study, sponsored by Romark Laboratories L.C..
- Completed
- Registry status
- Phase 3
- Development phase
- 1,756
- Enrollment target
NCT03605862 is a Phase 3 study that has completed, run by Romark Laboratories L.C.. The registered enrollment target is 1,756 participants.
The verdict
NCT03605862, a Phase 3 study, has completed, sponsored by Romark Laboratories L.C..
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,756 participants
- Enrollment target
Study Summary
Trial to evaluate efficacy and safety of nitazoxanide in the treatment of colds due to Enterovirus/Rhinovirus infection
Interventions
- DRUG Placebo
- DRUG Nitazoxanide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,756 participants |
| Start Date | 2018-09-11 |
| Est. Completion | 2019-02-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03605862
The ClinicalTrials.gov registry entry for NCT03605862 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,756 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Romark Laboratories L.C., which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03605862 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03605862 about?
NCT03605862 is a clinical study titled "Efficacy and Safety of Nitazoxanide in the Treatment of Colds Due to Enterovirus/Rhinovirus Infection". Trial to evaluate efficacy and safety of nitazoxanide in the treatment of colds due to Enterovirus/Rhinovirus infection
What is the current status of trial NCT03605862?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,756 participants. The study started on 2018-09-11. Estimated completion is 2019-02-04.
What interventions are being tested in trial NCT03605862?
The interventions under investigation include: Placebo (DRUG), Nitazoxanide (DRUG).
Who is sponsoring clinical trial NCT03605862?
This trial is sponsored by Romark Laboratories L.C., which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.